Subscribe

What are you looking for?

Main Menu

明報新聞網

恒瑞醫藥與GSK簽約 潛在總金額120億美元 曾升逾10%

Future Wealths
Future Wealths
28 7 月, 2025
One Min Read
10 Views
0 Comments
恒瑞醫藥(1276)與GSK簽約，將HRS-9821項目的全球獨家權利和至多11個項目的全球獨家許可的獨家選擇權（不包括中國大陸、香港、澳門及台灣）有償許可給GSK。如果所有項目均獲得行使選擇權且所有里程碑均已實現，恒瑞將有資格獲得未來基於成功開發、註冊和銷售里程碑付款的潛在總金額約120億美元

原文: https://finance.mingpao.com/fin/instantf/20250728/1753667434028/%e6%81%92%e7%91%9e%e9%86%ab%e8%97%a5%e8%88%87gsk%e7%b0%bd%e7%b4%84-%e6%bd%9b%e5%9c%a8%e7%b8%bd%e9%87%91%e9%a1%8d120%e5%84%84%e7%be%8e%e5%85%83-%e6%9b%be%e5%8d%87%e9%80%be10

Last Update: 28 7 月, 2025

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept